Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 3/20 | 0.41 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.41 |
| ▸ | ITGAV | P06756 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.41 |
| ▸ | ITGAL | P20701 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 6/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 6/20 | 0.39 |
| ▸ | RELA | Q04206 | 6/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.31 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.31 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2663986 | 0.80 | NFKB1 (0.37) | ITGB1ITGA5ITGB3ITGB2ITGAV | |
| SCHEMBL10673332 | 0.80 | ITGB3 (0.34) | ITGB1ITGA5ITGB3ITGB2ITGAV | |
| SCHEMBL18194639 | 0.77 | NFKB1 (0.41) | NFKB1NFKB2RELANLRP3 | |
| SCHEMBL16614334 | 0.77 | NFKB1 (0.44) | NFKB1NFKB2RELANLRP3 | |
| SCHEMBL2663977 | 0.77 | PTGS1 (0.36) | NFKB1NFKB2RELATSHR | |
| SCHEMBL16614389 | 0.77 | NFKB1 (0.41) | NFKB1NFKB2RELANLRP3ALDH1A1 | |
| SCHEMBL2663989 | 0.76 | — | — | |
| SCHEMBL2663978 | 0.72 | — | — | |
| SCHEMBL16614295 | 0.72 | NFKB1 (0.40) | NFKB1NFKB2RELANLRP3 | |
| SCHEMBL18194627 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1805196-A1 | SUBSTITUTED ADENINES AND THE USE THEREOF | AstraZeneca AB (SE) | 2007-07-11 | — | — | EP | disclosed |
| US-20070099930-A1 | Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| WO-2006040558-A1 | SUBSTITUTED ADENINES AND THE USE THEREOF | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099930-A1 | Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase | GCK, GCKR, GPR119 | ITGB1 4724/4885ITGA5 4693/4885ITGB3 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.